Loading page content…
Loading page content…
Loading contract search results…
Loading contract details…
| Source: | Find a Tender Service (FTS) |
| Notice Type: | Award notice |
| Buyer: | NHS Greater Glasgow and Clyde |
| Main Category: | Goods |
| Procurement Method: | Award procedure without prior publication of a call for competition |
| Method Rationale: | In order to award this contract compliantly, NHSGGC will follow Regulation 33. (b)where the works, supplies or services can be supplied only by a particular economic operator for any of the following reasons (ii)competition is absent for technical reasons. There are several commercial kits available for screening for SMA. This means if an alternative kit is used, SMA can be detected but not the variability or severity of this disease. The screening pathway established in Scotland by clinicians includes measurement of SMN1 and also measurement of SMN2 copy numbers. Therefore, to allow the laboratory to fulfil the Scottish screening pathway, SMN2 copy numbers must be measured in addition to the SMN1 deletion. The only identified solution is the proposed awarded kit. This adheres to the recommended screening pathway in Scotland. The benefit to the patient is that the full severity of the disease will be known at the initial appointment with the clinical team. In traditional pathways the patient will have to wait for diagnostic testing. Patients with the most severe forms of SMA have very severe symptoms caused by muscle wastage. This results in reduced movement, often resulting in an inability to sit or walk, and the need for breathing and feeding tubes. If the baby is able to start treatment before these symptoms present, they will likely never develop these symptoms. By knowing the severity of the disease as early as possible, gives the best chance for treatment to be given pre-symptomatically, thus reducing the morbidity and morality associated with this disease. In addition to this, there is significant published evidence to show that having the disease severity known at the initial appointment reduces anxiety for the family. No other commercial kits for SMA screening include the SMN2 copy number. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. |
View Original Notice
Access the full notice on the official portal
🤝 Need a consortium or subcontracting partner?
SMEs & Primes team up to win opportunities like this. Find partners on the board.
Awarded to
| Award status: | Active |
The Scottish Newborn Screening Laboratory has been commissioned to participate in the in-service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee. NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement is to screen dried blood spot samples from newborn babies for Spinal Muscular Atrophy (SMA).
CivTech 12 - Challenge 12.4 - How can technology improve both the efficiency and the patient experience in NHS transport, starting with renal services?
NHS Greater Glasgow and Clyde · WAC-649000
Interpreting, Communication Support and Transcription Services
NHS Greater Glasgow and Clyde · WAC-647843
NHSGGC Walk & Talk Service
NHS Greater Glasgow and Clyde · WAC-638244
Pipeline status
Not addedImports the contract into your BidWriter pipeline · Qualify before you commit to bid
Need help writing this bid?
Our specialists write winning tender responses. Free consultation, no obligation.
Book a free consultation →| Tender Status: | Closed |
| Estimated Value (ex. VAT): | Not specified |
| Release Date: | 19 March 2026 |
| Application Deadline: | — |
| Procurement ID (OCID): | ocds-h6vhtk-066e98 |
| Notice Reference: | 025039-2026 |